2025-522587-33-00招募中2 期
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Occurrence of at least 1 TEAE during the trial.
研究概览
简要总结
To evaluate the safety and tolerability of TAK-360 based on the posttreatment adverse event profile.
研究设计
- 分配方式
- Randomized
- 主要目的
- Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360
- 盲法
- Double (Subject, Investigator, Monitor, Carer)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •The participant is willing and able to understand and fully comply with trial procedures and requirements in the opinion of the investigator.
- •The participant has provided informed consent (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any trial procedures.
- •The participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form (ICF) and any required privacy authorization before the initiation of any trial procedures.
- •The participant is aged 18 to 70 years, inclusive, at the time of signing the ICF. Note: Adult age for the purpose of informed consent may differ by region. Only legal adults should be randomized into the trial
- •The participant has a body mass index within the range 18 to 40 kg/m2 (inclusive).
- •The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or ICSD-3 Text Revision diagnosis of narcolepsy type 1 (narcolepsy with cataplexy; NT1) supported by test results.
- •The participant is positive for the HLA genotype HLA-DQB1*06:02 (positive results for either homozygous or heterozygous alleles will be considered “positive” and acceptable) or results from radioimmunoassay indicate the participant’s CSF OX/hypocretin-1 concentration is ≤110 pg/mL (or less than one-third of the mean values obtained in normal participants within the same standardized assay). Note: Previous HLA results are acceptable if available for review by the investigator and provided for inclusion in the eCRF. In the EU, teh UK, and Switzerland, only previously obtained HLA and/or CSF OX results may be used to confirm eligibility. These historical results should be reviewed by the investigator and provided for inclusion in the eCRF.
- •The participant is judged by the investigator to be sufficiently healthy to participate in the trial, on the basis of clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead electrocardiogram, and vital sign measurements performed at the screening visit and before the first dose of trial intervention.
- •The participant agrees to follow the contraceptive requirements.
- •In line with country-specific regulations, participants may need to be affiliated with a Social Security Scheme or be a beneficiary of one.
排除标准
- •The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with excessive daytime sleepiness.
- •The participant is a trial site employee or an immediate family member of or in a dependent relationship with a trial site employee (for example, spouse, parent, child, or sibling) who is involved in the conduct of this trial or may consent under duress.
- •The participant: has a history of myocardial infarction; thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or an ongoing condition that would preclude enrollment in the view of the investigator.
- •The participant consumes excessive amounts of caffeine
- •The participant currently consumes excessive amounts of alcohol
- •The participant has a usual bedtime later than 1:00 AM, an occupation requiring nighttime shift work or variable shift work within the past 6 months, travel with significant jet lag or plans for travel with significant jet lag
- •The participant, in the opinion of the investigator or subinvestigator, is unlikely to comply with the protocol or is unsuitable for any other reason.
- •The participant is considered to be vulnerable, as defined by local regulations and if exclusion is required by local regulations. Examples of vulnerable persons are persons under safeguard of justice, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care without their consent, persons admitted to a health or social establishment for purposes other than research, persons of full age who are subject to a legal protection measure (guardianship or curatorship), and persons unable to express their consent.
- •The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
- •The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell carcinoma; these participants may be included after approval by the medical monitor).
- •The participant has a clinically significant history of head injury or head trauma.
- •The participant has had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks before the screening visit.
- •The participant has a history of epilepsy, seizure, or convulsion (except for a single febrile seizure in childhood).
- •The participant has a history of cerebral ischemia, transient ischemic attack (<5 years from screening), intracranial aneurysm, or arteriovenous malformation.
- •The participant has a current history of significant multiple and/or severe allergies (for example, food, drug, or latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food which in the investigator’s opinion poses a significant risk to the participant to participate in trial.
- •The participant has a known hypersensitivity to any component of the formulation of TAK-360 or related compounds.
- •The participant is unable to refrain from or anticipates using excluded food products.
- •The participant has participated in another investigational drug trial, in which they received the investigational drug. The interval window from the previous trial will be derived from the date of the last dose of investigational drug in the previous trial to the screening visit of the current trial.
- •The participant plans to participate in any other interventional trial while participating in TAK-360-2004 or has previously participated in another part in TAK-360-
- •The participant has ever discontinued an orexin receptor 2 agonist, including TAK-360, due to a safety or tolerability issue.
- •The participant has a positive test result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or HIV antibody/antigen at screening.
- •The participant has a positive pregnancy test result at screening or Day -2 or is breastfeeding.
- •The participant has a positive urine screen result for drugs of abuse and/or positive alcohol test result at screening or Day -
- •An exception at screening is made for stimulants or other drugs the participant has been prescribed. Products containing cannabidiol (but not tetrahydrocannabinol) may be allowed throughout the trial, at the discretion of the investigator.
结局指标
主要结局
Occurrence of at least 1 TEAE during the trial.
Occurrence of at least 1 TEAE during the trial.
次要结局
- 1. Parts A and B: Change from baseline in mean sleep latency from the MWT at Week 6.
- 2. Parts A and B: Change from baseline in ESS total score at Week 6.
- 3. Parts A and B: WCR at Week 6.
研究者
Sana Ghafoor
Scientific
Takeda Development Center Americas Inc.
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subjects With Moderate-to-Severe Plaque Psoriasis2023-505842-24-00Takeda Development Center Americas Inc.686
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis2023-505841-22-00Takeda Development Center Americas Inc.235
招募中
2 期
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System AtrophyMultiple System Atrophy2023-509876-40-00Takeda Development Center Americas Inc.101
招募中
2 期
First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer2023-504012-16-00Takeda Development Center Americas Inc., Takeda Development Center Americas Inc.56
招募中
3 期
A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the drug TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)2024-513839-24-00Baxalta Innovations GmbH30